Drugs Containing Excipient (Inactive Ingredient) SHELLAC

Branded drugs containing SHELLAC excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	RETEVMO	selpercatinib	0002-3977	SHELLAC	2038-04-10
ER Squibb & Sons LLC	REYATAZ	atazanavir	0003-3624	SHELLAC
Genentech Inc	CELLCEPT	mycophenolate mofetil	0004-0260	SHELLAC
Genentech Inc	TAMIFLU	oseltamivir phosphate	0004-0802	SHELLAC
Allergan Inc	KADIAN	morphine sulfate	0023-6011	SHELLAC
Sanofi-Aventis US LLC	FLOMAX	tamsulosin hydrochloride	0024-5837	SHELLAC

Generic drugs containing SHELLAC excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	selpercatinib	0002-3977	SHELLAC
ER Squibb & Sons LLC	atazanavir	0003-3624	SHELLAC
Genentech Inc	mycophenolate mofetil	0004-0260	SHELLAC
Genentech Inc	oseltamivir phosphate	0004-0802	SHELLAC
Allergan Inc	morphine sulfate	0023-6011	SHELLAC
Sanofi-Aventis US LLC	tamsulosin hydrochloride	0024-5837	SHELLAC

Last updated: August 2, 2026

ecutive summary: Shellac is a niche, naturally derived pharmaceutical excipient used mainly for enteric coating, moisture protection, taste masking, and modified drug release. Its commercial value is tied to functional coating performance rather than active-ingredient exclusivity. Public companies generally do not disclose shellac revenue separately, and no reliable public dataset establishes a shellac-only pharmaceutical market size or forecast. The financial trajectory is therefore best assessed through demand in oral solid dosage forms, raw-lac supply, purification capacity, regulatory qualification, and competition from synthetic and polymeric coating systems.

Shellac Pharmaceutical Excipient Market Dynamics and Financial Trajectory

What is pharmaceutical-grade shellac used for?

Shellac is a natural resin secreted by the lac insect, primarily associated with production in India and Southeast Asia. Pharmaceutical-grade shellac is processed, purified, and standardized for use as a functional excipient rather than as an active pharmaceutical ingredient.

Its principal pharmaceutical applications are:

Application	Functional role	Commercial relevance
Enteric coating	Resists gastric conditions and dissolves at higher intestinal pH	Core pharmaceutical use
Moisture barrier	Protects hygroscopic tablets and pellets	Supports stability-sensitive products
Taste masking	Reduces contact between drug substance and taste receptors	Relevant to pediatric and orally disintegrating products
Modified release	Controls liquid penetration and drug diffusion	Usually used in combination with other polymers
Tablet polishing	Provides surface gloss and handling protection	Lower-value application
Capsule and multiparticulate coating	Improves appearance and protects coated units	Used in pellets, beads, and granules

Shellac is particularly relevant to oral solid dosage forms containing moisture-sensitive, bitter, or acid-labile ingredients. It is also used in pharmaceutical and nutraceutical products where a natural or animal-derived coating is commercially acceptable.

Shellac does not function as a universal replacement for modern enteric polymers. Its performance can vary with grade, purification, plasticizer content, coating weight, pH, storage conditions, and processing method.

How large is the pharmaceutical shellac market?

No authoritative public source provides an audited global revenue figure for pharmaceutical shellac alone. Market-research reports often combine shellac with food additives, industrial coatings, confectionery, cosmetics, or broader pharmaceutical excipients. Those totals cannot be treated as pharmaceutical shellac revenue.

The market is best characterized as a small specialty-excipient segment within the wider coating and oral-solid-dosage market. Its economic profile has four defining characteristics:

1. Pharmaceutical demand is smaller than food, confectionery, and industrial demand.
2. Qualification requirements support higher pricing for pharmaceutical grades.
3. Supplier revenue is concentrated in refined and standardized grades rather than raw shellac.
4. Purchasers can often substitute synthetic polymers, although substitution may require reformulation and regulatory work.

The absence of separate public revenue disclosure limits precise market-size and company-share calculations. Shellac suppliers are generally private, diversified, or report shellac within broader resin and excipient categories.

What drives shellac excipient demand?

Growth in oral solid dosage manufacturing

Tablets, pellets, granules, and multiparticulate systems remain major pharmaceutical delivery formats. Shellac benefits when manufacturers need a coating that provides moisture resistance, taste masking, or delayed release without developing a completely new delivery platform.

Demand is strongest in:

• Generic and branded tablets with enteric-release requirements
• Nutraceutical and supplement products
• Pediatric formulations requiring taste masking
• Fixed-dose combinations containing incompatible ingredients
• Products manufactured in humid climates
• Multiparticulate and pellet-based dosage forms

The excipient is also relevant to contract development and manufacturing organizations that maintain coating platforms for multiple customers.

Natural-ingredient positioning

Shellac can support a natural-origin formulation narrative in certain markets. That advantage is limited by regulatory and consumer acceptance of insect-derived materials. Some customers avoid shellac because of vegetarian, vegan, religious, ethical, or animal-origin policies.

The commercial effect is product-specific. Natural-origin demand can support premium applications, while animal-origin restrictions can eliminate shellac from other formulations.

Moisture and stability requirements

Shellac is valued for its film-forming and barrier properties. Increased use of highly hygroscopic active ingredients, amorphous solid dispersions, and moisture-sensitive formulations can support demand for protective coatings.

The value proposition is strongest when shellac reduces packaging requirements, improves tablet stability, or avoids a more complex coating system. It is weaker where a synthetic polymer provides better control of dissolution, process consistency, or global regulatory acceptance.

What are the main supply-chain risks for pharmaceutical shellac?

Dependence on biological raw material

Shellac supply depends on lac insect populations, host trees, climate conditions, agricultural practices, and regional collection systems. Raw-lac production is not equivalent to synthetic polymer production because supply cannot be expanded instantly through ordinary chemical manufacturing.

Potential supply pressures include:

• Crop variability
• Weather and drought
• Disease affecting host trees or lac insects
• Labor availability
• Export restrictions
• Regional political disruption
• Competing food and industrial demand
• Changes in forest and agricultural policy

A poor harvest can affect both price and lead time. Pharmaceutical buyers therefore place greater value on validated suppliers, inventory buffers, and documented traceability than industrial users.

Processing and purification capacity

Raw shellac is not suitable for direct pharmaceutical use. Refining, decolorization, filtration, drying, milling, and specification control determine whether a product can be qualified for pharmaceutical manufacturing.

The supply chain has several potential bottlenecks:

Supply-chain stage	Main risk
Lac cultivation and collection	Biological and climatic variability
Primary processing	Inconsistent resin quality
Refining	Color, odor, wax, and impurity control
Pharmaceutical finishing	Particle size, microbiological quality, and batch consistency
Documentation	GMP, traceability, allergen, animal-origin, and regulatory records
Global distribution	Long lead times and inventory exposure

For a pharmaceutical customer, switching suppliers can require new specifications, coating trials, stability studies, and regulatory submissions. That switching cost gives qualified producers more commercial protection than raw-material suppliers.

What regulatory status does shellac have as a pharmaceutical excipient?

Shellac is an excipient, not an approved drug substance. Its regulatory status depends on the jurisdiction, grade, dosage form, route of administration, and intended function.

The U.S. Food and Drug Administration’s Inactive Ingredient Database is the principal public reference for excipients used in approved drug products. Inclusion in the database does not constitute independent approval of every shellac grade or every proposed use. FDA review remains product-specific through the applicable drug application pathway [1].

The main regulatory considerations are:

• Identity and purity
• Residual solvents
• Heavy metals and elemental impurities
• Microbiological quality
• Pesticide or agricultural residues
• Batch-to-batch dissolution performance
• Animal-origin documentation
• Allergen and contaminant controls
• Compatibility with the active ingredient
• Stability under proposed storage conditions

European and other regulatory authorities evaluate excipients through the finished medicinal product dossier. The excipient must be supported by appropriate quality documentation and a risk assessment consistent with the product’s route and use. The European Medicines Agency’s excipient guidance requires applicants to address excipient function, safety, quality, and justification in the product dossier [2].

What is the Orange Book status of shellac?

Shellac has no Orange Book listing because the Orange Book lists approved drug products and associated patents or exclusivity information, not excipients as standalone commercial products [3].

This means:

Question	Shellac status
Is shellac an Orange Book-listed drug?	No
Does shellac have standalone FDA drug exclusivity?	No
Can shellac have a Drug Master File?	A supplier may submit confidential quality information, but that does not create product exclusivity
Can a shellac-containing drug be patented?	Yes, if the formulation, process, or use meets patentability standards
Can a generic applicant challenge shellac itself under Paragraph IV?	No

What patents protect pharmaceutical shellac formulations?

The basic composition and ordinary pharmaceutical use of shellac are generally vulnerable to prior-art challenges because shellac has been used for coatings and pharmaceutical applications for decades. The strongest enforceable rights are more likely to concern specific formulations or processes, including:

• Shellac combined with plasticizers or co-polymers
• Controlled dissolution profiles
• Specific coating compositions
• Layered coating systems
• Shellac-based taste-masking systems
• Low-temperature or aqueous coating processes
• Methods for improving adhesion to tablets or pellets
• Stabilization against cracking, aging, or pH-related dissolution changes
• Specific drug-shellac combinations

Patent protection must be evaluated claim by claim. A formulation patent may cover a particular ratio, process parameter, dissolution threshold, or product architecture without protecting shellac as a substance.

How strong is the shellac patent estate?

The shellac excipient itself has a weak standalone patent position because it is an established natural material. Patent strength is higher in narrow, application-specific claims supported by comparative dissolution, stability, coating uniformity, or bioavailability data.

Patent category	Likely strength
Shellac as a natural resin	Low
Shellac as a general tablet coating	Low to moderate
Defined shellac-polymer formulation	Moderate
Drug-specific shellac coating	Moderate to high if data support unexpected performance
Manufacturing process with tight parameters	Moderate
Broad claims covering enteric use generally	Low

Patent searches should cover the assignee, inventors, formulation ratios, coating process, target drug, and jurisdiction. A search limited to the word “shellac” will miss patents that describe the resin by chemical or functional terms.

Are there Paragraph IV challenges or shellac-related patent litigation?

There is no standalone Paragraph IV pathway for shellac because it is not an approved drug product with Orange Book-listed patents. Paragraph IV litigation can arise only when a generic applicant challenges patents listed for a shellac-containing branded drug.

Potential litigation targets include:

• Drug-specific formulation patents
• Method-of-use patents
• Delayed-release dosage-form claims
• Coating-layer claims
• Manufacturing-process patents
• Crystalline or particle-form claims involving the active ingredient

The litigation risk therefore attaches to the finished drug product, not to the excipient market generally. A generic company may use a different coating polymer, design around a shellac formulation claim, or argue that a shellac-containing formulation does not fall within the patent claims.

No broadly recognized, shellac-specific patent litigation docket establishes a market-wide exclusivity barrier. Litigation exposure is product-specific and must be assessed through FDA listings, patent assignment records, court dockets, and settlement terms.

When does shellac lose exclusivity?

Shellac does not have a single exclusivity expiration date. It is a mature excipient with no standalone regulatory exclusivity period.

The relevant timelines are:

Right or approval	Typical consequence
Shellac composition knowledge	Generally public and mature
Supplier quality documentation	Confidential, but not market exclusivity
Formulation patent	Expires according to its jurisdiction-specific term
Drug-product patent	May delay generic approval or launch
Regulatory exclusivity for a finished drug	Applies to the drug product, not shellac
Trade secret coating process	Can persist while secrecy and practical control remain

The commercial barrier is therefore qualification and performance replication, not excipient exclusivity.

How does shellac compare with competing coating polymers?

Shellac competes with cellulose derivatives, methacrylate copolymers, polyvinyl acetate systems, polyethylene glycol-containing systems, and other functional coating materials.

Attribute	Shellac	Synthetic enteric polymers
Origin	Natural resin	Chemically manufactured
Enteric performance	Usable but formulation-dependent	Often more programmable
Moisture barrier	Strong in selected systems	Varies by polymer
Batch consistency	Dependent on purification and grade	Usually more standardized
Animal-origin concern	Present	Usually lower
Natural-label value	Potentially favorable	Usually limited
Global acceptability	Market-specific	Often broader
Formulation flexibility	Moderate	Often higher
Supply predictability	Exposed to biological harvests	Usually more scalable
Substitution cost	Low for simple coatings, higher for validated products	Reformulation and stability work may be required

Shellac retains value where its coating properties, regulatory history, or customer positioning outweigh concerns about supply, origin, and process variability.

What is the financial trajectory for pharmaceutical shellac?

A precise shellac-only revenue forecast is not supported by public financial disclosures. The defensible financial view is a stable-to-moderate-growth specialty-excipient profile with commodity volatility.

Revenue growth can come from:

• Expansion of oral solid dosage manufacturing
• Higher demand for moisture-barrier coatings
• Growth in pediatric and taste-masked medicines
• Premium pharmaceutical grades
• Greater use of multiparticulate delivery systems
• Qualification of additional regional suppliers

Margin pressure can come from:

• Synthetic-polymer substitution
• Raw-lac price increases
• Crop failures
• Customer concentration
• Long qualification cycles
• Restrictions on animal-derived ingredients
• Procurement consolidation among pharmaceutical manufacturers

Supplier economics are likely to divide into two tiers. Refined pharmaceutical grades can command higher margins because they require documentation, testing, and customer qualification. Lower-grade shellac is more exposed to food, confectionery, and industrial pricing.

What revenue exposure do pharmaceutical companies have to shellac?

Large pharmaceutical companies generally do not report shellac revenue or shellac procurement as a separate financial line. The direct revenue exposure is therefore concentrated in excipient suppliers and resin processors, while branded-drug companies capture value through finished products.

Shellac price changes are unlikely to materially affect the cost of a major pharmaceutical product on a portfolio basis. The greater exposure is operational:

• A supply interruption can delay batch release.
• A grade change can require coating revalidation.
• A formulation change can trigger stability and regulatory work.
• A failed dissolution profile can create manufacturing waste.

The excipient’s financial importance is higher for suppliers than for most drug manufacturers.

Which generic launch risks exist for shellac-containing drugs?

Generic launch risk depends on the finished product’s patents, regulatory pathway, and formulation complexity.

A generic applicant may pursue four strategies:

1. Use the same shellac grade and challenge relevant patents.
2. Use a different shellac formulation that avoids the claims.
3. Replace shellac with another enteric or barrier polymer.
4. Seek approval after relevant drug-product patents and exclusivities expire.

The highest barrier arises when the branded product has a narrow dissolution profile, a complex multiparticulate system, or manufacturing know-how that is difficult to reproduce. Shellac alone rarely creates the barrier.

What licensing deals affect shellac?

No major publicly disclosed licensing structure is associated with shellac as a standalone pharmaceutical excipient. Commercial arrangements are more likely to involve:

• Supply agreements
• Private-label manufacturing
• Regional distribution rights
• Quality agreements
• Technology-transfer arrangements
• Contract coating or formulation services

Licensing value may arise when a company owns a protected shellac-based formulation or a coating process, but the asset is then a drug-delivery technology rather than shellac itself.

What geographic markets are most important for shellac?

The commercial chain is geographically divided:

Region	Strategic role
India and Southeast Asia	Raw-lac production and primary processing
Europe	Specialty pharmaceutical formulation and regulatory qualification
North America	Drug development, generic manufacturing, and regulated procurement
China	Pharmaceutical manufacturing and excipient demand
Latin America	Generic-drug and nutraceutical demand
Middle East and Africa	Import-dependent pharmaceutical supply

Global suppliers must manage regional differences in animal-origin policies, excipient standards, labeling, import controls, and customer qualification.

What manufacturing and intellectual-property barriers matter most?

Manufacturing barriers include purification consistency, color control, dissolution reproducibility, microbial control, and stable coating performance. These barriers are practical rather than exclusive. A competitor can generally develop an alternative grade, but the process may require months of formulation work and validation.

The most defensible supplier advantages are:

• Reliable raw-lac sourcing
• Validated pharmaceutical-grade processing
• Strong quality systems
• Long customer qualification histories
• Consistent coating performance
• Regulatory documentation
• Regional inventory and technical support

These advantages can protect customer relationships even when patent protection is limited.

Key takeaways

• Shellac is a mature specialty excipient used primarily in coatings for oral solid dosage forms.
• Its main functions are enteric protection, moisture resistance, taste masking, and modified release.
• No reliable public source establishes a shellac-only pharmaceutical market size or supplier revenue forecast.
• The financial trajectory is likely stable to moderately growing, with exposure to raw-lac harvest cycles and synthetic-polymer substitution.
• Shellac has no standalone Orange Book listing, FDA exclusivity period, or Paragraph IV challenge pathway.
• Patent value is concentrated in specific shellac formulations, coating processes, and drug-product applications.
• The strongest commercial barriers are supplier qualification, process consistency, documentation, and customer switching costs.
• Generic-launch risk attaches to shellac-containing finished drugs rather than to shellac as an excipient.
• Animal-origin restrictions and biological supply variability are the main structural risks.
• Pharmaceutical-grade shellac can command a premium over industrial material when quality, traceability, and regulatory documentation are validated.

FAQs about pharmaceutical shellac

Is shellac safe as a pharmaceutical excipient?

Shellac can be used as a pharmaceutical excipient when the selected grade meets applicable quality specifications and is supported in the finished product dossier. Safety assessment remains product-specific and depends on route, dose, impurities, and intended use.

Is shellac suitable for vegan medicines?

Shellac is derived from lac insects and is generally unsuitable for products marketed as vegan. Manufacturers must assess animal-origin requirements and regional labeling expectations before use.

Can shellac replace enteric polymers such as methacrylate copolymers?

Shellac can replace some enteric or barrier polymers, but substitution requires formulation development, dissolution testing, stability studies, and regulatory assessment. Performance is not automatically equivalent.

Does shellac have a USP-NF monograph?

Shellac may be referenced through applicable pharmacopeial, food, or supplier specifications, but a manufacturer must verify the current compendial status and the exact requirements for the intended market and dosage form.

Who bears the greatest financial risk from shellac price increases?

Refiners, excipient distributors, and manufacturers with limited inventory buffers bear the direct cost risk. Large pharmaceutical companies usually face greater operational and revalidation risk than material-cost exposure.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. European Medicines Agency. (2018). Guideline on the excipients in the dossier for application for marketing authorisation of a medicinal product. https://www.ema.europa.eu/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-overview

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. Rockville, MD: U.S. Pharmacopeial Convention.

5. Joint FAO/WHO Expert Committee on Food Additives. (n.d.). Compendium of food additive specifications: Shellac. Food and Agriculture Organization of the United Nations and World Health Organization.